SAN DIEGO, Dec. 21, 2017 /PRNewswire/ -- Arena
Pharmaceuticals, Inc. (NASDAQ: ARNA), today announced that
Amit D. Munshi, the Company's
President and Chief Executive Officer, will present a corporate
update at the 36th Annual J.P. Morgan Healthcare Conference on
Wednesday, January 10, at
2:30 p.m. PST. The conference
will take place January 8-11, 2018,
at the Westin St. Francis Hotel in San
Francisco.
A live audio webcast of the presentation will be available under
the investor relations section of Arena's website at
www.arenapharm.com. A replay of the presentation will be available
for 30 days following the event.
About Arena Pharmaceuticals
Arena Pharmaceuticals is
focused on developing novel, small molecule drugs with optimized
receptor pharmacology and pharmacokinetics designed to deliver
broad clinical utility across several therapeutic areas. Arena's
proprietary pipeline includes potentially first- or best-in-class
programs. Its most advanced investigational clinical
programs are ralinepag (APD811) which will be commencing a Phase 3
program for pulmonary arterial hypertension (PAH) and etrasimod
(APD334) in Phase 2 evaluation a broad range of autoimmune or
immune-mediated conditions. The Company is also evaluating
APD371 in Phase 2a evaluation for the treatment of pain associated
with Crohn's disease. In addition, Arena has collaborations with
the following pharmaceutical companies: Eisai Co., Ltd. and Eisai
Inc. (Belviq®), Axovant Sciences (nelotanserin - Phase
2), Boehringer Ingelheim International GmbH (preclinical), and
Everest Medicines Limited (Greater
China and limited other regions for ralinepag and
etrasimod).
Forward-Looking Statements
Certain statements in this
press release are forward-looking statements that involve a number
of risks and uncertainties. These forward-looking statements may be
accompanied by words such as "focused on," "designed to," "will,"
"may," or words of similar meaning, or by the fact that they do not
relate strictly to historical or current facts. Such
forward-looking statements include statements about the upcoming
presentation; and Arena's focus, programs and collaborations. For
such statements, Arena claims the protection of the Private
Securities Litigation Reform Act of 1995. Actual events or results
may differ materially from Arena's expectations. Factors that could
cause actual results to differ materially from the forward-looking
statements include clinical programs may not proceed at the time or
in the manner expected or at all, as well as those disclosed in
Arena's filings with the Securities and Exchange Commission. These
forward-looking statements represent Arena's judgment as of the
time of this release. Arena disclaims any intent or obligation to
update these forward-looking statements, other than as may be
required under applicable law.
Corporate
Contact:
Kevin R. Lind
Arena Pharmaceuticals, Inc.
Executive Vice President and
Chief Financial
Officer
klind@arenapharm.com
858.210.3636
Media Contact:
Matt Middleman, M.D.
LifeSci Public Relations
matt.middleman@lifescipublicrelations.com
646.627.8384
View original
content:http://www.prnewswire.com/news-releases/arena-pharmaceuticals-to-present-at-the-36th-annual-jp-morgan-healthcare-conference-on-january-10-300574238.html
SOURCE Arena Pharmaceuticals, Inc.